global
diseas
burden
john
hopkin
univers
http
coronavirusjhuedumaphtml
million
infect
death
worldwid
social
distanc
citi
countri
around
world
remain
mean
avail
limit
impact
viru
transmiss
time
unpreced
respons
world
biomed
research
commun
seek
identifi
treatment
includ
antivir
drug
vaccin
develop
current
clinic
observ
indic
infect
rang
inappar
nonsymptomat
infect
respiratori
ill
present
spike
fever
dri
cough
accompani
high
rate
humanhuman
transmiss
one
seriou
complic
corona
viru
diseas
develop
atyp
upper
respiratori
tract
pneumonia
pose
major
challeng
clinician
term
diseas
manag
abnorm
uncontrol
product
cytokin
observ
critic
ill
patient
pneumonia
ensu
uncontrol
cytokin
storm
patient
central
involv
exacerb
symptom
diseas
develop
repres
major
factor
contribut
mortal
sens
diseas
share
similar
viral
diseas
sar
mer
influenza
develop
cytokin
storm
warn
sign
diseas
escal
support
observ
retrospect
studi
patient
show
infect
patient
present
clinic
mild
symptom
minor
patient
progress
declin
infect
eventu
die
acut
respiratori
distress
syndrom
ard
multipl
organ
dysfunct
syndrom
mod
guidelin
diagnosi
treatment
infect
pneumonia
first
publish
januari
th
recommend
first
time
cytokin
monitor
appli
improv
cur
rate
reduc
mortal
view
sever
morbid
mortal
pneumonia
review
current
understand
treatment
human
coronaviru
infect
perspect
dysregul
immun
respons
emerg
reemerg
virus
ebola
zika
chikungunya
dengu
sar
mer
led
numer
global
public
health
crise
recent
year
continu
threaten
public
health
secur
unfortun
virus
often
difficult
control
due
lack
approv
antivir
drug
vaccin
addit
two
novel
coronavirus
emerg
global
health
threat
sinc
name
sever
acut
respiratori
syndrom
coronaviru
sarscov
transmit
countri
middl
east
respiratori
syndrom
coronaviru
merscov
transmit
countri
sever
pneumonia
caus
pathogen
human
coronavirus
hcov
often
associ
induc
hypercytokinemia
also
term
cytokin
storm
immunocompet
individu
uncontrol
overproduct
inflammatori
cytokin
contribut
acut
lung
injuri
acut
respiratori
distress
syndrom
ard
secret
multipl
cytokin
also
term
cytokin
releas
syndrom
cr
close
j
u
r
n
l
p
r
e
p
r
f
relat
develop
clinic
symptom
exampl
caus
fever
chill
headach
dizzi
fatigu
caus
flulik
symptom
similar
fever
gener
malais
fatigu
also
caus
vascular
leakag
cardiomyopathi
lung
injuri
acutephas
protein
synthesi
import
target
cr
induc
adopt
cell
therapi
lead
vascular
leakag
activ
complement
coagul
cascad
lead
characterist
symptom
sever
cr
diffus
intravascular
coagul
dic
noteworthi
like
caus
cardiomyopathi
promot
myocardi
dysfunct
often
observ
patient
cr
addit
activ
endotheli
cell
may
also
one
hallmark
sever
cr
endotheli
dysfunct
lead
capillari
leakag
hypotens
coagulopathi
figur
taken
togeth
studi
argu
virusinduc
immunopatholog
event
play
crucial
role
fatal
pneumonia
observ
hcov
infect
develop
cytokin
storm
potenti
fatal
immun
condit
character
rapid
prolifer
hyperactiv
cell
macrophag
natur
killer
cell
overproduct
inflammatori
cytokin
chemic
mediat
releas
immun
nonimmun
cell
viral
infect
aberr
releas
proinflammatori
factor
lead
lung
epitheli
endotheli
cell
apoptosi
damag
lung
microvascular
alveolar
epitheli
cell
barrier
lead
vascular
leakag
alveolar
edema
hypoxia
uncontrol
product
proinflammatori
factor
contain
gmcsf
chemokin
togeth
reactiv
oxygen
speci
caus
ard
lead
pulmonari
fibrosi
death
sarscov
infect
patient
high
level
serum
proinflammatori
cytokin
chemokin
detect
case
sever
diseas
compar
patient
uncompl
sar
mer
infect
high
level
serum
proinflammatori
cytokin
chemokin
likewis
observ
sever
diseas
compar
mild
moder
diseas
contrast
sar
mer
doctor
wuhan
central
south
hospit
found
level
gscf
tnf
significantli
elev
blood
sever
ill
patient
compar
patient
mild
ill
level
blood
sever
group
higher
mild
group
furthermor
histolog
examin
biopsi
sampl
obtain
patient
die
sever
infect
show
increas
concentr
highli
proinflammatori
cell
suggest
cell
hyperactiv
contributesdin
part
sever
immun
injuri
patient
pulmonari
examin
patient
earli
phase
pneumonia
also
reveal
patchi
inflammatori
cell
infiltr
howev
patholog
result
earli
stage
pneumonia
requir
confirm
short
aberr
releas
multipl
cytokin
appear
trigger
cytokin
storm
produc
immunopathogen
damag
tissu
organ
even
immun
respons
seek
suppress
erad
viru
figur
j
u
r
n
l
p
r
e
p
r
f
view
observ
therapeut
strategi
treat
cytokin
storm
pathogenesi
sever
pneumonia
deserv
special
attent
accord
current
guidanc
support
therapi
remain
import
manag
strategi
pneumonia
includ
supplement
oxygen
therapi
conserv
fluid
manag
empir
antimicrobi
applic
time
need
noteworthi
use
glucocorticoid
remain
controversi
current
guidanc
recommend
corticosteroid
use
lung
injuri
shock
except
set
clinic
trial
howev
clinic
set
frontlin
physician
china
tend
use
corticosteroid
prudent
low
moder
dosag
patient
infect
period
sar
epidem
corticosteroid
gener
use
clinician
immunomodulatori
treatment
accord
clinic
feedback
could
bring
earli
benefici
chang
includ
declin
fever
resolut
radiograph
lung
infiltr
improv
oxygen
howev
studi
indic
opposit
clinic
outcom
systemat
review
sar
mer
influenza
infect
indic
surviv
benefit
possibl
harm
avascular
necrosi
psychosi
diabet
delay
viral
clearanc
secondari
infect
corticosteroid
opinion
use
corticosteroid
recommend
patient
hcov
infect
although
corticosteroid
may
use
prudent
critic
ill
patient
treatment
patient
infect
clinician
pay
close
attent
impact
immun
inflammatori
factor
releas
sever
effect
cytokin
storm
blocker
therapeut
method
report
clinic
process
pneumonia
window
period
diagnosi
occurr
mod
day
window
major
patient
tend
improv
wherea
patient
progress
sever
pneumonia
mortal
improv
prognosi
suggest
patient
pneumonia
given
immunotherapi
treatment
time
diagnosi
order
block
possibl
subsequ
cytokin
storm
earli
use
immunolog
intervent
evalu
patient
mod
may
reduc
mortal
sever
patient
figur
posit
one
strategi
receiv
consider
attent
face
use
convalesc
plasma
also
call
passiv
antibodi
therapi
treat
patient
advanc
diseas
treatment
use
plasma
patient
surviv
infect
provid
neutral
antibodi
viru
antibodi
avail
activ
immedi
limit
time
exampl
one
studi
five
patient
critic
ill
mechan
ventil
receiv
convalesc
plasma
day
admit
hospit
shenzhen
china
patient
improv
three
discharg
day
hospit
two
patient
stabl
condit
well
control
clinic
evalu
strategi
current
ongo
light
posit
anecdot
respons
anoth
potenti
treatment
involv
use
monoclon
antibodi
siltuximab
johnson
johnson
use
previous
treat
consequ
cytokin
storm
follow
cart
cell
therapi
cancer
becom
key
point
cr
origin
describ
bcell
differenti
macrophag
granulocyt
induct
signific
proinflammatori
pyrogen
properti
given
chronic
overproduct
patient
monoclon
antibodi
may
benefici
control
cytokin
releas
also
inhibitor
secukinumab
novarti
use
specif
treatment
sever
patient
pneumonia
control
cell
activ
addit
observ
indic
express
level
low
level
high
patient
sever
pneumonia
suggest
cell
subset
cytokin
level
could
use
one
predictor
transit
mild
sever
pneumonia
pegyl
nonpegyl
interferon
ifn
intens
studi
time
howev
case
hcov
infect
result
ifn
therapi
mix
predict
anim
human
hcov
infect
model
earli
applic
ifn
slightli
benefici
reduc
viral
load
improv
clinic
outcom
howev
delay
ifn
administr
benefitscompar
placebo
group
earli
applic
ifn
ribavirin
moder
improv
diseas
sever
without
affect
mortal
use
sifalimumab
monoclon
antibodi
produc
multipl
ifn
subtyp
medimmun
examin
clinic
could
hold
promis
situat
constitut
ifn
product
earli
use
ifn
benefici
effect
sarscovinfect
anim
model
although
time
ifn
treatment
crucial
determin
cours
diseas
use
receptor
inhibitor
antagonist
could
consid
approach
avoid
excess
inflammatori
reaction
late
stage
sever
hcov
infect
sinc
sarscov
merscov
infect
mainli
airway
epitheli
cell
stimul
antivir
gene
express
cell
without
overstimul
immun
system
might
option
therapi
hcov
infect
oxid
phospholipid
oxpl
demonstr
promot
acut
lung
injuri
increas
product
cytokineschemokin
lung
macrophag
via
signal
influenza
viru
iav
infect
mice
recent
studi
therapeut
administr
antagonist
eritoran
protect
mice
lethal
iav
infect
decreas
level
oxpl
inflammatori
cytokineschemokin
pathogen
human
coronavirus
caus
acut
lung
injuri
promot
product
oxpl
lung
strategi
oxpl
suppress
use
eritoran
boc
scienc
similar
compound
may
valu
control
hcov
induc
inflamm
signal
transduct
receptor
mous
endotheli
cell
j
u
r
n
l
p
r
e
p
r
f
nfect
influenza
viru
shown
contribut
pathogenesi
inflamm
respons
target
antagon
inhibit
recruit
inflammatori
cell
limit
proinflammatori
cytokinechemokin
releas
reduc
mortal
morbid
induc
influenza
viru
antagon
may
consid
potenti
therapi
hcovinfect
individu
limit
cytokin
respons
result
studi
anim
model
born
claim
imm
pali
pathogen
role
process
fatal
hcov
infect
mice
cardiac
inflamm
model
system
administr
optim
lipid
nanoparticl
includ
small
interf
rna
sirna
effect
degrad
mrna
destroy
imm
recruit
inflammatori
site
thu
improv
outcom
diseas
hcov
singlechain
rna
virus
agonist
synthet
singlechain
rna
analog
stimul
imm
caus
exuber
inflammatori
respons
therefor
imm
specif
signal
may
promot
excess
inflammatori
respons
caus
hcov
infect
therefor
antagonist
target
approach
allevi
inflamm
reaction
could
use
continu
renal
replac
therapi
crrt
may
benefit
sever
patient
remov
potenti
harm
compon
maintain
haemodynam
metabol
statu
addit
convent
aim
maintain
renal
function
crrt
use
regul
immun
respons
patient
sepsi
goal
regul
circul
level
inflammatori
cytokin
mediat
shown
studi
demonstr
remov
inflammatori
mediat
contain
cytokin
complement
complement
factor
crrt
present
need
welldesign
clinic
trial
evalu
efficaci
treatment
regimen
infect
patient
develop
system
inflammatori
respons
syndrom
sir
mod
character
uncontrol
releas
inflammatori
mediat
give
rise
cytokin
storm
contribut
increas
mortal
ard
summari
experiment
requir
understand
chang
immun
respons
patient
infect
mechan
abnorm
cytokin
express
pneumonia
accur
predict
target
intervent
cours
pneumonia
essenti
improv
patient
surviv
figur
summari
process
onset
pathogenesi
potenti
treatment
option
virusinduc
cytokin
storm
